课题基金 / 基金详情

Functional Tolerance to Islet Allografts

Functional Tolerance to Islet Allografts
同种异体胰岛移植物的功能耐受性
批准号:
7140441
负责人:
Nora E Sarvetnick
金额:
$18.15万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-06-15 至 2007-05-31

项目摘要

项目成果

Nora E Sarvetnick的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Autoimmune diseases such as Type 1 diabetes (T1D) manifest themselves clinically when insulin producing cells are already completely lost. At this point, the only cure for diabetes is the replacement of these insulin-producing cells. However, patients receiving such grafts suffer from lifetime immunosuppressive treatments, leading to increased propensity to infection. If functional resistance.- to allograft rejection could be conferred on these grafts the requirement for immunosuppression would be avoided aid the quality of life for those receiving allografts would be greatly enhanced. In this exploratory R21 application we propose a new hypothesis for the induction of resistance to islet allograft rejection. Since these grafts are destroyed by cytokines produced by infiltrating cells, we proposed to engineer islets that are unresponsive to these pathogenic cytokines. Two different experimental designs are proposed in this application. In the first set of studies we will determine whether targeted expression of SOCS-1, a protein that inhibits interferon signaling, can ameliorate graft responses. We present compelling preliminary data stating that this aim is feasible and shows promising results. In the second set of studies we plan to down-modulate SOCS-3 gene expression to determine if modulation of IL-6 responses, with increased responses to IL-10, could play a pro-survival role in graft survival. Extensive mechanistic studies, to understand both systemic and localized allograft responses, are proposed for each paradigm. These studies should lead to new methods for inducing resistance to islet allograft rejection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
海外基金